Last reviewed · How we verify
Bencycloquidium Bromide Nasal Spray
Bencycloquidium bromide is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce nasal secretions and congestion.
Bencycloquidium bromide is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce nasal secretions and congestion. Used for Allergic rhinitis with rhinorrhea, Vasomotor rhinitis.
At a glance
| Generic name | Bencycloquidium Bromide Nasal Spray |
|---|---|
| Also known as | BILITING |
| Sponsor | Yingu Pharmaceutical Co., Ltd |
| Drug class | Anticholinergic agent |
| Target | Muscarinic acetylcholine receptor (M3) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Allergy |
| Phase | FDA-approved |
Mechanism of action
As a quaternary ammonium anticholinergic compound, bencycloquidium bromide antagonizes M3 muscarinic receptors on nasal mucosa, decreasing mucus production and secretion. When delivered as a nasal spray, it provides local anticholinergic effects to alleviate rhinorrhea and nasal congestion associated with allergic rhinitis and other nasal conditions.
Approved indications
- Allergic rhinitis with rhinorrhea
- Vasomotor rhinitis
Common side effects
- Nasal dryness
- Epistaxis
- Headache
- Pharyngeal irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: